Any feedback?
Literature summary for 1.3.1.9 extracted from
- Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach (2008), Chem. Biol. Drug Des., 72, 444-449.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | WYW is a potential lead compound for the development of new anti-tuberculosis drugs | Mycobacterium tuberculosis |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| isoniazid | - |
Mycobacterium tuberculosis |  |
| WYW | tripeptide inhibitor, identified using a structure-based approach | Mycobacterium tuberculosis | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Mycobacterium tuberculosis | P9WGR1 | - |
- |
| Mycobacterium tuberculosis H37Rv | P9WGR1 | - |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| enoyl acyl carrier protein reductase | - |
Mycobacterium tuberculosis |
| InhA | - |
Mycobacterium tuberculosis |
Cofactor
| Cofactor | Comment | Organism | Structure |
|---|---|---|---|
| NADH | - |
Mycobacterium tuberculosis | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
